142 / 1631
Conclusions (1)
•
Anti -PD-1-pathway-blocking agents highly active in HL but more limited
efficacy in other lymphomas. Mechanistic insights are emerging in HL
•
Currently very large number of combination therapies involving anti-PD-
1/PD-L1 agents and conventional chemotherapies, targeted therapies, or
other immunotherapies are being studied
•
CAR-T cells look promising in relapsed and refractory DLBCL and other
lymphoid malignancies. Efficacy and validity of delivery require on-going
further international studies
•
Clinical trials outrunning new immunological scientific insights.